Cargando…
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor
BACKGROUND: The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant chronic m...
Autores principales: | Marit, Michael R., Chohan, Manprit, Matthew, Natasha, Huang, Kai, Kuntz, Douglas A., Rose, David R., Barber, Dwayne L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420867/ https://www.ncbi.nlm.nih.gov/pubmed/22916261 http://dx.doi.org/10.1371/journal.pone.0043437 |
Ejemplares similares
-
Identification of Critical Residues of the Mycobacterial Dephosphocoenzyme A Kinase by Site-Directed Mutagenesis
por: Walia, Guneet, et al.
Publicado: (2011) -
Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
por: Hubbard, Stevan R.
Publicado: (2018) -
Enu Mutagenesis Identifies a Novel Platelet Phenotype in a Loss-Of-Function Jak2 Allele
por: Anderson, Nicole M., et al.
Publicado: (2013) -
A Bipolar Clamp Mechanism for Activation of Jak-Family Protein Tyrosine Kinases
por: Barua, Dipak, et al.
Publicado: (2009) -
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events
por: Kim, Hani, et al.
Publicado: (2011)